SPSB3

Summary

SPSB3 (splA/ryanodine receptor domain and SOCS box containing 3, HGNC:30629) is a protein-coding gene on chromosome 16p13.3, encoding SPRY domain-containing SOCS box protein 3 (Q6PJ21). Substrate-recognition component of a cullin-5-RING E3 ubiquitin-protein ligase complex (ECS complex, also named CRL5 complex), which mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as CGAS and SNAI1.

Enables ubiquitin-like ligase-substrate adaptor activity. Involved in several processes, including negative regulation of cGAS/STING signaling pathway; negative regulation of epithelial to mesenchymal transition; and protein K48-linked ubiquitination. Part of Cul5-RING ubiquitin ligase complex. Is active in nucleus.

Source: NCBI Gene 90864 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 2 total
• MANE Select transcript: NM_080861

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30629
Approved symbol	SPSB3
Name	splA/ryanodine receptor domain and SOCS box containing 3
Location	16p13.3
Locus type	gene with protein product
Status	Approved
Aliases	SSB-3
Ensembl gene	ENSG00000162032
Ensembl biotype	protein_coding
OMIM	611659
Entrez	90864

Gene structure

Transcript identifiers

Ensembl transcripts: 28 — 19 protein_coding, 9 retained_intron

ENST00000301717, ENST00000563668, ENST00000563705, ENST00000563741, ENST00000564070, ENST00000564709, ENST00000565550, ENST00000566339, ENST00000567868, ENST00000568416, ENST00000569380, ENST00000569769, ENST00000890579, ENST00000890580, ENST00000890581, ENST00000890582, ENST00000890583, ENST00000890584, ENST00000890585, ENST00000890586, ENST00000890587, ENST00000890588, ENST00000890589, ENST00000890590, ENST00000965197, ENST00000965198, ENST00000965199, ENST00000965200

RefSeq mRNA: 2 — MANE Select: NM_080861 NM_001324081, NM_080861

CCDS: CCDS32365

Canonical transcript exons

ENST00000566339 — 7 exons

Exon	Start	End
ENSE00002621258	1782502	1782571
ENSE00002623095	1776712	1777443
ENSE00003471659	1781358	1781495
ENSE00003492934	1778134	1778321
ENSE00003541994	1777747	1777872
ENSE00003589455	1778435	1778612
ENSE00003643619	1777946	1778048

Expression profiles

Bgee: expression breadth ubiquitous, 284 present calls, max score 99.40.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.1462 / max 84.1634, expressed in 1782 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
155869	10.9929	1782
155870	0.3068	24
155868	0.1533	53

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	99.40	gold quality
right hemisphere of cerebellum	UBERON:0014890	97.58	gold quality
cerebellar hemisphere	UBERON:0002245	97.52	gold quality
cerebellar cortex	UBERON:0002129	97.44	gold quality
granulocyte	CL:0000094	97.41	gold quality
lower esophagus mucosa	UBERON:0035834	97.41	gold quality
upper leg skin	UBERON:0004262	97.22	gold quality
cerebellum	UBERON:0002037	97.00	gold quality
skin of hip	UBERON:0001554	96.89	gold quality
skin of leg	UBERON:0001511	96.71	gold quality
mucosa of stomach	UBERON:0001199	96.67	gold quality
endothelial cell	CL:0000115	96.61	gold quality
right lobe of liver	UBERON:0001114	96.56	gold quality
skin of abdomen	UBERON:0001416	96.53	gold quality
apex of heart	UBERON:0002098	96.36	gold quality
left ovary	UBERON:0002119	96.29	gold quality
gastrocnemius	UBERON:0001388	96.24	gold quality
left adrenal gland cortex	UBERON:0035825	96.24	gold quality
cervix squamous epithelium	UBERON:0006922	96.10	gold quality
adrenal cortex	UBERON:0001235	96.03	gold quality
left adrenal gland	UBERON:0001234	95.99	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.94	gold quality
right ovary	UBERON:0002118	95.92	gold quality
right adrenal gland	UBERON:0001233	95.90	gold quality
right adrenal gland cortex	UBERON:0035827	95.87	gold quality
body of pancreas	UBERON:0001150	95.84	gold quality
amniotic fluid	UBERON:0000173	95.69	gold quality
body of stomach	UBERON:0001161	95.63	gold quality
zone of skin	UBERON:0000014	95.59	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	95.57	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.34
E-MTAB-4850	no	585.34

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

20 targeting SPSB3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-7845-5P	99.88	64.88	771
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-548AU-3P	99.70	68.22	1373
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-584-3P	99.35	67.69	1082
HSA-MIR-7515	99.31	68.22	1795
HSA-MIR-3678-3P	99.31	67.10	1432
HSA-MIR-3154	98.94	66.55	1455
HSA-MIR-6501-3P	98.71	67.45	1480
HSA-MIR-2467-3P	98.65	67.18	1969
HSA-MIR-6842-3P	98.07	66.33	1325
HSA-MIR-1910-5P	97.42	66.36	844
HSA-MIR-4475	97.36	66.95	761
HSA-MIR-4690-3P	97.02	64.72	981
HSA-MIR-5685	97.02	64.34	1004
HSA-MIR-1258	96.08	67.74	700
HSA-MIR-3943	95.87	64.57	523

Literature-anchored findings (GeneRIF, showing 2)

• Low SPSB3 expression is associated with lymph node metastasis in Ovarian and esophageal squamous cell carcinoma. (PMID:29059170)
• The CRL5-SPSB3 ubiquitin ligase targets nuclear cGAS for degradation. (PMID:38418882)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	spsb3a	ENSDARG00000077737
mus_musculus	Spsb3	ENSMUSG00000024160
rattus_norvegicus	Spsb3	ENSRNOG00000015300
drosophila_melanogaster	CG10516	FBGN0036549

Paralogs (4): SPSB2 (ENSG00000111671), SPSB1 (ENSG00000171621), FBXO45 (ENSG00000174013), SPSB4 (ENSG00000175093)

Protein

Protein identifiers

SPRY domain-containing SOCS box protein 3 — Q6PJ21 (reviewed: Q6PJ21)

All UniProt accessions (2): Q6PJ21, H3BP12

UniProt curated annotations — full annotation on UniProt →

Function. Substrate-recognition component of a cullin-5-RING E3 ubiquitin-protein ligase complex (ECS complex, also named CRL5 complex), which mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as CGAS and SNAI1. The ECS(SPSB3) complex catalyzes ‘Lys-48’-linked ubiquitination of nuclear CGAS in cycling cells, leading to its degradation. Recognizes and binds nucleosome-bound CGAS: ubiquitination and degradation of nuclear CGAS during G1 and G2 phases is required to promote low intranuclear CGAS abundance before the next mitotic cycle. The ECS(SPSB3) complex also mediates ubiquitination and degradation of phosphorylated SNAI1.

Subunit / interactions. Substrate-recognition component of the ECS(SPSB3) complex, composed of SPSB3, CUL5, ELOB, ELOC and RNF7/RBX2. Interacts with MET.

Subcellular location. Nucleus.

Domain organisation. The SOCS box domain mediates the interaction with the Elongin BC complex, an adapter module in different E3 ubiquitin ligase complexes.

Pathway. Protein modification; protein ubiquitination.

Similarity. Belongs to the SPSB family.

RefSeq proteins (2): NP_001311010, NP_543137* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001496	SOCS_box	Domain
IPR001870	B30.2/SPRY	Domain
IPR003877	SPRY_dom	Domain
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR035754	SPRY_SPSB3	Domain
IPR043136	B30.2/SPRY_sf	Homologous_superfamily
IPR050672	FBXO45-Fsn/SPSB_families	Family

Pfam: PF00622

UniProt features (34 total): strand 15, turn 5, sequence conflict 4, domain 2, region of interest 2, helix 2, mutagenesis site 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
8OL1	ELECTRON MICROSCOPY	3.5
8OKX	ELECTRON MICROSCOPY	3.51

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6PJ21-F1	77.01	0.63

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (2):

Position	Phenotype
160–162	abolished interaction with cgas; when associated with 259-a–a-262.
259–262	abolished interaction with cgas; when associated with 160-a–a-162.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-8951664	Neddylation
R-HSA-392499	Metabolism of proteins
R-HSA-597592	Post-translational protein modification

MSigDB gene sets: 170 (showing top): STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_EPITHELIAL_TO_MESENCHYMAL_TRANSITION, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_POSITIVE_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS, GOBP_REGULATION_OF_IMMUNE_RESPONSE, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_MESENCHYMAL_CELL_DIFFERENTIATION, BLALOCK_ALZHEIMERS_DISEASE_UP, KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN, GOBP_REGULATION_OF_RESPONSE_TO_STRESS, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_PROTEIN_POLYUBIQUITINATION, STONER_ESOPHAGEAL_CARCINOGENESIS_UP

GO Biological Process (8): negative regulation of epithelial to mesenchymal transition (GO:0010719), proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161), protein K48-linked ubiquitination (GO:0070936), negative regulation of cGAS/STING signaling pathway (GO:0160049), epithelial to mesenchymal transition (GO:0001837), ubiquitin-dependent protein catabolic process (GO:0006511), protein ubiquitination (GO:0016567), cGAS/STING signaling pathway (GO:0140896)

GO Molecular Function (2): ubiquitin-like ligase-substrate adaptor activity (GO:1990756), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), cytosol (GO:0005829), SCF ubiquitin ligase complex (GO:0019005), Cul5-RING ubiquitin ligase complex (GO:0031466)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Post-translational protein modification	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cullin-RING ubiquitin ligase complex	2
epithelial to mesenchymal transition	1
regulation of epithelial to mesenchymal transition	1
negative regulation of cell differentiation	1
negative regulation of multicellular organismal process	1
ubiquitin-dependent protein catabolic process	1
proteasomal protein catabolic process	1
protein polyubiquitination	1
negative regulation of cytoplasmic pattern recognition receptor signaling pathway	1
cGAS/STING signaling pathway	1
mesenchymal cell differentiation	1
protein ubiquitination	1
modification-dependent protein catabolic process	1
protein modification by small protein conjugation	1
cytoplasmic pattern recognition receptor signaling pathway	1
enzyme-substrate adaptor activity	1
binding	1
intracellular membrane-bounded organelle	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

720 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SPSB3	CISH	Q9NSE2	763
SPSB3	SPSB1	Q96BD6	494
SPSB3	FBXL14	Q8N1E6	490
SPSB3	SPSB2	Q99619	478
SPSB3	KLHL38	Q2WGJ6	450
SPSB3	ANKRD29	Q8N6D5	444
SPSB3	TRIM21	P19474	422
SPSB3	SPSB4	Q96A44	422
SPSB3	OR4A5	Q8NH83	419
SPSB3	BTNL3	Q6UXE8	418
SPSB3	BTNL8	Q6UX41	416
SPSB3	BTN2A1	P78408	411
SPSB3	FBXO11	Q86XK2	410
SPSB3	FBXL5	Q9UKA1	398
SPSB3	OR4C12	Q96R67	396

IntAct

67 interactions, top by confidence:

A	B	Type	Score
PGBD1	ZNF24	psi-mi:“MI:0914”(association)	0.900
CUL5	SOCS2	psi-mi:“MI:0914”(association)	0.880
CDK13	CCNK	psi-mi:“MI:0914”(association)	0.830
SMYD1	ADSS2	psi-mi:“MI:0914”(association)	0.780
SPSB3	ENKD1	psi-mi:“MI:0915”(physical association)	0.720
ENKD1	SPSB3	psi-mi:“MI:0915”(physical association)	0.720
CUL5	SOCS7	psi-mi:“MI:0914”(association)	0.640
NUMB	SLC1A1	psi-mi:“MI:0914”(association)	0.640
GNPTG	GNPTAB	psi-mi:“MI:0914”(association)	0.620
	SPSB3	psi-mi:“MI:0915”(physical association)	0.560
SPSB3		psi-mi:“MI:0915”(physical association)	0.560
SPSB3	NUMBL	psi-mi:“MI:0915”(physical association)	0.560
SPSB3	ZNF396	psi-mi:“MI:0915”(physical association)	0.560
GRN	SPSB3	psi-mi:“MI:0915”(physical association)	0.560
RPGR	NPHP1	psi-mi:“MI:0914”(association)	0.560
GPN3	POLR3A	psi-mi:“MI:0914”(association)	0.530
POLR1C	POLR3A	psi-mi:“MI:0914”(association)	0.530
RNF7	SOCS7	psi-mi:“MI:0914”(association)	0.530
HSP90AB1	SPSB3	psi-mi:“MI:0915”(physical association)	0.400
MAPK8IP2	SPSB3	psi-mi:“MI:0915”(physical association)	0.370
CSNK2B	SPSB3	psi-mi:“MI:0915”(physical association)	0.370
SPSB3	CFTR	psi-mi:“MI:0915”(physical association)	0.370
CUL5	DDX3X	psi-mi:“MI:0914”(association)	0.350

BioGRID (57): SPSB3 (Two-hybrid), SPSB3 (Two-hybrid), SPSB3 (Affinity Capture-RNA), SPSB3 (Affinity Capture-MS), SPSB3 (Affinity Capture-MS), SPSB3 (Two-hybrid), SPSB3 (Affinity Capture-MS), SPSB3 (Affinity Capture-MS), SPSB3 (Affinity Capture-MS), SPSB3 (Affinity Capture-MS), SPSB3 (Affinity Capture-MS), SPSB3 (Affinity Capture-MS), SPSB3 (Affinity Capture-MS), SPSB3 (Affinity Capture-MS), SPSB3 (Affinity Capture-MS)

ESM2 similar proteins: A1L0Y2, A2ALK8, A2ARP1, A2Z8S0, A4IFG2, A8XT88, B1AVZ0, B3M1E1, B3P4N5, B4GZ20, B4HJC0, B4KA23, B4LVS8, B4NKI9, B4PVH6, B4QVW6, M9MRI4, O35242, O76050, P0C644, P26045, Q18223, Q29B63, Q29RQ5, Q3MHZ2, Q3UJK4, Q571F5, Q5M870, Q5NCX5, Q5PQR3, Q5R881, Q6PFW1, Q6PJ21, Q75G68, Q8BVR6, Q8C726, Q8CJC5, Q8R516, Q91YL3, Q91ZY8

Diamond homologs: A1Z6E0, A8QGZ7, A8XT88, B0X9V1, B3MDR0, B3NRP1, B4F739, B4GBN7, B4HQ29, B4J6Q0, B4KNC5, B4LMQ3, B4MR59, B4P4K8, B4QE02, O88838, P0C2W1, P0CH38, Q16XV7, Q18223, Q290L5, Q3MHZ2, Q571F5, Q5E9X6, Q5M877, Q6NZ03, Q6PJ21, Q7QGL9, Q7ZXY1, Q8K3B1, Q8R5B6, Q96A44, Q96BD6, Q99619, Q9D5L7, Q9V6L9, Q28DT9, Q5M9B1

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 56 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Neutrophil degranulation	9	5.5×	3e-03

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of cell migration	7	7.9×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

2 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2635 predictions. Top by Δscore:

Variant	Effect	Δscore
16:1777441:CAC:C	acceptor_gain	1.0000
16:1777442:ACCT:A	acceptor_loss	1.0000
16:1777444:CTGGA:C	acceptor_loss	1.0000
16:1777741:CCTCA:C	donor_loss	1.0000
16:1777742:CTCA:C	donor_loss	1.0000
16:1777743:TCAC:T	donor_loss	1.0000
16:1777745:ACCT:A	donor_loss	1.0000
16:1777746:C:T	donor_loss	1.0000
16:1777756:T:TA	donor_gain	1.0000
16:1777757:C:A	donor_gain	1.0000
16:1777873:C:CC	acceptor_gain	1.0000
16:1778129:CTTA:C	donor_loss	1.0000
16:1778130:TTACC:T	donor_loss	1.0000
16:1778131:TAC:T	donor_loss	1.0000
16:1778132:A:AC	donor_gain	1.0000
16:1778132:AC:A	donor_gain	1.0000
16:1778133:C:CA	donor_gain	1.0000
16:1778133:CC:C	donor_gain	1.0000
16:1778133:CCA:C	donor_gain	1.0000
16:1778133:CCAT:C	donor_gain	1.0000
16:1778133:CCATG:C	donor_gain	1.0000
16:1778319:AATCT:A	acceptor_loss	1.0000
16:1778320:ATCT:A	acceptor_loss	1.0000
16:1778321:TCT:T	acceptor_loss	1.0000
16:1778322:C:CA	acceptor_loss	1.0000
16:1778322:C:CC	acceptor_gain	1.0000
16:1778323:T:G	acceptor_loss	1.0000
16:1778428:CG:C	donor_gain	1.0000
16:1778433:A:AC	donor_gain	1.0000
16:1778434:C:CC	donor_gain	1.0000

AlphaMissense

2332 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:1777995:G:C	F182L	1.000
16:1777995:G:T	F182L	1.000
16:1777997:A:G	F182L	1.000
16:1778144:C:T	G161D	1.000
16:1778175:A:G	W151R	1.000
16:1778175:A:T	W151R	1.000
16:1778307:A:G	W107R	1.000
16:1778307:A:T	W107R	1.000
16:1777376:G:C	S263R	0.999
16:1777376:G:T	S263R	0.999
16:1777378:T:G	S263R	0.999
16:1777383:G:T	A261D	0.999
16:1777392:G:A	S258F	0.999
16:1777392:G:T	S258Y	0.999
16:1777393:A:G	S258P	0.999
16:1777394:G:C	C257W	0.999
16:1777396:A:G	C257R	0.999
16:1777776:A:G	L231P	0.999
16:1777797:A:G	L224P	0.999
16:1777809:A:T	I220N	0.999
16:1777826:G:C	F214L	0.999
16:1777826:G:T	F214L	0.999
16:1777828:A:G	F214L	0.999
16:1777872:C:A	G199V	0.999
16:1777872:C:T	G199D	0.999
16:1777952:A:C	Y197D	0.999
16:1777954:G:A	S196F	0.999
16:1777955:A:G	S196P	0.999
16:1777957:A:G	L195P	0.999
16:1777960:C:T	G194D	0.999

dbSNP variants (sampled 300 via entrez): RS1000513546 (16:1776370 CAG>C), RS1000560342 (16:1778867 A>G), RS1000967235 (16:1779124 C>T), RS1001138988 (16:1784052 C>A,T), RS1001221004 (16:1780501 G>A), RS1001626436 (16:1780661 G>A), RS1001868867 (16:1783851 G>A,T), RS1002250848 (16:1783589 A>C), RS1002479993 (16:1783220 C>G,T), RS1003003991 (16:1781528 G>T), RS1003051504 (16:1781757 C>T), RS1003647232 (16:1782601 G>A), RS1003856156 (16:1779708 G>A,C), RS1004116517 (16:1779572 G>A,C), RS1004344436 (16:1776594 C>T)

Disease associations

OMIM: gene MIM:611659 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST010320_29	PR interval	3.000000e-09
GCST010321_49	PR interval	1.000000e-09
GCST90000025_76	Appendicular lean mass	2.000000e-23
GCST90000026_8	Appendicular lean mass	5.000000e-14
GCST90000027_33	Appendicular lean mass	4.000000e-11
GCST90002400_167	Plateletcrit	2.000000e-09

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004462	PR interval
EFO:0004980	appendicular lean mass
EFO:0007985	platelet crit

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, increases expression	2
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression	2
Arsenic	affects methylation, affects cotreatment, decreases expression, increases abundance	2
Tunicamycin	increases expression	2
Valproic Acid	increases methylation, affects expression	2
aristolochic acid I	increases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
trichostatin A	affects expression	1
beta-lapachone	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
cobaltous chloride	increases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
perfluorooctane sulfonic acid	increases expression	1
K 7174	increases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
ICG 001	increases expression	1
licochalcone B	increases expression	1
jinfukang	affects cotreatment, increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Bortezomib	increases expression	1
Resveratrol	decreases expression	1
Temozolomide	increases expression	1
Acrolein	increases abundance, affects cotreatment, increases oxidation	1
Air Pollutants	increases abundance, increases oxidation, affects cotreatment	1
Cisplatin	increases expression, affects cotreatment	1
Diuron	decreases expression	1
Estradiol	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.